Pivotal role of Smad3 in a mouse model of T cell-mediated hepatitis
Related Experiment Video
Updated: Jul 10, 2026

The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Michael Kremer1, Ashley W Perry, Richard J Milton
1Center for Alcohol Studies, University of North Carolina, Chapel Hill, NC 27599, USA. mkremer@med.unc.edu
Unlabelled:
Transforming growth factor beta (TGFbeta) promotes hepatocellular apoptosis and suppresses hepatic lymphocyte responses in part through activation of Smad3. The purpose of the current study was to determine the importance of Smad3 signaling in an experimental model of autoimmune hepatitis induced by concanavalin A (ConA), a process involving T cell activation and hepatocellular apoptosis. C57Bl/6 wild-type (Wt) or Smad3-deficient (Smad3(-/-)) mice were injected intravenously with 15 mg/kg ConA or vehicle. Nine hours post ConA injection, Wt mice presented with severe hepatitis as assessed by increased liver transferases. This injury was associated with eosinophil accumulation and preceded at 3 hours post-injection by significant increases in hepatic T helper 1 (interferon gamma) and T helper 2 (interleukin-4) cytokine production. Absence of Smad3 significantly blunted hepatocellular injury 9 hours post ConA injection, which was associated with reduced early T helper 1 and T helper 2 cytokine production and eosinophil accumulation. Smad3(-/-) livers also showed significant reductions in hepatocellular apoptosis as assessed by terminal UTP nick-end labeling when compared to ConA-treated Wt mice in conjunction with reduced caspase 3 cleavage, which was likely mediated by a Smad3-dependent inhibition of the survival factor extracellular signal-regulated kinase 1/2. In vitro, Smad3(-/-) hepatocytes were resistant to TGFbeta-induced apoptosis, and this protection was dependent on extracellular signal-regulated kinase activation.
Conclusion:
Together, these results show, for the first time, the significance of Smad3 signaling in autoimmune hepatitis, underlining the control of Smad3-dependent TGFbeta signaling on proinflammatory cytokine production, eosinophil recruitment, and hepatocellular apoptosis. Interruption of this pathway could be beneficial clinically to limit acute fulminant liver pathologies.
Insights
Smad3 signaling is crucial in autoimmune hepatitis, controlling inflammation and liver cell death. Blocking this pathway may help treat severe liver diseases.
Area of Science:
- Immunology
- Hepatology
- Molecular Biology
Background:
- Transforming growth factor beta (TGFbeta) influences liver cell apoptosis and immune responses via Smad3.
- Autoimmune hepatitis involves T cell activation and liver cell death.
Purpose of the Study:
- To investigate the role of Smad3 signaling in concanavalin A (ConA)-induced autoimmune hepatitis.
Main Methods:
- C57Bl/6 wild-type (Wt) or Smad3-deficient (Smad3(-/-)) mice were injected with ConA.
- Liver injury, cytokine production, and apoptosis were assessed.
Main Results:
- Smad3 deficiency significantly reduced ConA-induced liver injury, inflammation, and hepatocellular apoptosis.
- Smad3(-/-) hepatocytes were resistant to TGFbeta-induced apoptosis.
Conclusions:
- Smad3 signaling is significant in autoimmune hepatitis, regulating inflammation and liver cell death.
- Targeting Smad3-dependent TGFbeta signaling may offer therapeutic benefits for acute liver failure.

